Bremelanotide in HSDD: two phase 3 trials · 2019
Two controlled trials assessed desire, distress, sexual-event counts and adverse events. Results differed by endpoint; the trials evaluated a specific clinical formulation.
Read studyGX BIO LABS · Product artwork
PT-141, also known as bremelanotide, is a melanocortin-receptor agonist studied in defined clinical populations with sexual dysfunction.
Not currently available
Check COA availabilityCOA not yet available for this strength
Not for human or veterinary administration. Listed strength is a supplied specification; see the matching batch report for measured results.
Bremelanotide is a cyclic peptide that acts on melanocortin receptors. Two phase 3 trials enrolled premenopausal women with diagnosed hypoactive sexual desire disorder and evaluated a defined clinical formulation. Questionnaire measures of desire and related distress improved relative to placebo, while the change in the number of satisfying sexual events did not differ significantly between groups. Nausea, flushing and headache occurred more often with bremelanotide. These findings apply to the studied population and formulation. They do not establish general sexual enhancement or the quality, safety or clinical equivalence of a research vial.
Each source identifies what was studied and the limits of its findings. Published research is separate from this product’s batch COA.
Two controlled trials assessed desire, distress, sexual-event counts and adverse events. Results differed by endpoint; the trials evaluated a specific clinical formulation.
Read studyPT-141 is currently listed in 10 mg. Select a strength above to see its price, product image and current stock. Listed quantities are supplied specifications, not measured batch results.
No laboratory report is currently published for this compound. Request the available documentation before relying on any batch-specific measurement. A scientific paper is not a substitute for a COA.
A catalogue listing is not a laboratory measurement. Check original documentation for the selected strength and batch before relying on identity, purity or quantity information.